Drugs / BAY 3713372
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06914128 | Mar 2025 → Jun 2029 expected | — | Bayer | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 3713372 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06914128 ↗ |
| Action | Inhibit | “blocking the protein arginine N-methyltransferase 5 (PRMT5)” NCT06914128 ↗ |
| Route | Oral | “Daily oral administration” NCT06914128 ↗ |
| Target | PRMT5 | “blocking the protein arginine N-methyltransferase 5 (PRMT5)” NCT06914128 ↗ |